bmiMD review

bmiMD does the structural work properly: the microdose is its own product with its own checkout and its own published ladder, a genuine month-to-month rung exists so no prepaid term is forced on you, and every prepay total is shown up front. Then it charges exactly the same for it. Put the two ladders side by side and they are identical at all four plan lengths on both molecules, which means the entire benefit of choosing the low-dose product is that you receive less drug. No milligram figure is published anywhere for what any of it buys, so there is nothing to check that against either.

Vs median

$40/mo below the $169 median across the 242 of 373 programs we track that publish a plain monthly rate

Market

$59–$1300/mo is the full published spread in our ranking

Structure

Same price at every dose

Consult

Included in the price

Dietitian

Not included

Labs

Not required

Pricing

Flat at every dose

Price last updated

August 2026

bmiMD does not publicly identify the pharmacy that fills its prescriptions. No bloodwork is required before you start. A clinician review is included in the price.

bmiMD is a direct-to-consumer telehealth weight-loss and metabolic-health platform that says it connects patients to licensed clinicians in all 50 states, selling compounded semaglutide and tirzepatide alongside metformin, a naltrexone/bupropion/B6 combination and MIC+B12 injections. Care runs entirely online: a free quiz, a clinician review, and if a prescription is written it is filled by a licensed U.S. pharmacy and shipped, typically within 24 hours of the prescription. The pharmacy is never named — the site says only "state-licensed" and independently verified in registered labs — and neither 503A nor 503B is stated. There is no separate membership or consultation fee, and everything is cash-pay on prepaid one-, three-, six- or twelve-month terms.

Microdosing costs exactly what the full dose costs — $129/mo either way on semaglutide, $179/mo either way on tirzepatide, across all four rungs of an identical ladder. You pay full-dose money for less drug, and nothing on either page says so

• No milligram figure is published anywhere for what $129/mo actually buys; "calibrated, low-dose" is the entire description of the dose
• The three-month card on the tirzepatide microdose page prints a total that does not match its own monthly figure multiplied by three, and bmiMD's standard tirzepatide page prints the correct, higher total for the same rung
• A "limited time" countdown implies a discount, but no regular price is published against any rung, so there is nothing to check the discount against
• The compounding pharmacy is never named and neither 503A nor 503B is stated
• The $99 and $139 figures used in "starting as low as" copy are twelve-month prepay rungs requiring $1,188 or $1,668 paid up front
• Compounded GLP-1s are not FDA-approved, and intentional microdosing is off-label and unproven

bmiMD is one of 373 low-dose GLP-1 programs we track, and 242 of them publish a monthly rate you can read before signing up. The ranking lists every published price on one screen, ordered with the companies that pay us first — a mechanism we state there, on the page it applies to.

Intentional GLP-1 microdosing is off-label and unproven — no randomized trial has established that a sub-label dose does anything, and any dose belongs with a clinician who knows your history. If you are going to have that conversation, have it with real numbers.

• What the evidence actually shows
• Microdosing semaglutide
• Microdosing tirzepatide
• What a flat price costs at a low dose
• The true annual cost of a plan